BlueRun Ventures Becomes Inaugural Member of Capital Sub-Alliance in Synthetic Biology Industry Innovation Alliance

On April 27–28, 2023, the 4th Engineering Biology Innovation Conference, the 2nd China Synthetic Biology Academic Annual Meeting, and the 1st Asian Synthetic Biology Innovation Conference were held in Shenzhen. At the event, BlueRun Ventures, as one of the first investment institutions in the Synthetic Biology Industry Innovation Alliance, announced a partnership with the Shenzhen Engineering Biology Innovation Center to establish a Capital Sub-Alliance, reaching strategic cooperation on screening, incubation, resource allocation, and investment and financing for high-quality synthetic biology projects.

BlueRun Ventures stated: "As a cutting-edge interdisciplinary field integrating multiple domains, synthetic biology plays a critical role in the biopharmaceutical industry. Its broad scope means that industrial logic varies fundamentally across different sectors, and translating research into commercial outcomes requires diverse expertise and support. BlueRun Ventures is honored to work alongside our partners in the alliance to bridge capital and industry collaboration, promote the healthy development of the industrial ecosystem, and create more opportunities and momentum for the sector's growth."

The Synthetic Biology Industry Innovation Alliance is a non-profit consortium guided by the Shenzhen Science and Technology Innovation Commission and initiated by the Shenzhen Synthetic Biology Association. Serving as a platform for exchange among science, technology, industry, and capital, the alliance aims to bring together enterprises and individuals engaged in synthetic biology R&D, production, services, and applications, in collaboration with government, academia, industry, capital, and the public. It promotes domestic and international academic and industrial exchange to accelerate the development of synthetic biology industry clusters and ecosystems. The establishment of this Capital Sub-Alliance is designed to further accelerate the construction of synthetic biology industry clusters and ecosystems, strengthening the linkage between industry and capital in the synthetic biology space.

Guided by a technology-driven investment philosophy focused on identifying next-generation biotech companies aligned with industrial logic, BlueRun Ventures has already deployed capital across multiple leading innovative enterprises in AI-driven drug discovery, proteomics, advanced medical diagnostics, and cell therapy. The firm values technological innovation and convergence, with particular attention to interdisciplinary projects spanning brain-computer interfaces, automation equipment, DNA synthesis technology, biochips, and sensors.

This conference was hosted by the Shenzhen Municipal Development and Reform Commission, the Shenzhen Guangming District People's Government, Shenzhen University of Advanced Technology (preparatory), and the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences. It was co-organized by the Shenzhen Institute of Synthetic Biology, the School of Synthetic Biology at Shenzhen University of Advanced Technology (preparatory), the Shenzhen Engineering Biology Industry Innovation Center, the Shenzhen Synthetic Biology Association, and DeepTech. Under the theme "Synthetic Biology: The Engine of the Future Bioeconomy," the conference brought together domestic and international guests from government, industry, academia, research, and investment communities, as well as Asian synthetic biology representatives from Japan, South Korea, and Singapore. It focused on hot topics including synthetic biology technology innovation, industrial translation, and capital application. By integrating the innovation chain, industrial chain, capital chain, and talent chain of synthetic biology, the conference aimed to build a clustered synthetic biology industrial ecosystem and catalyze leapfrog development in the bioeconomy.

▶ More Content ◀

Originating in Silicon Valley, BlueRun Ventures was established in 2005 as a venture capital firm focused on early-stage startups.

The firm currently manages multiple USD and RMB dual-currency funds in China, with assets under management exceeding RMB 15 billion, making it one of the largest early-stage funds domestically. Its investment stage focuses on Pre-A and Series A rounds, covering hard tech and innovative interaction, enterprise technology, new consumer, and healthcare. It has invested in more than 150 startups, including Li Auto, Waterdrop, QingCloud, Guazi Used Car, Qudian, Songguo Mobility, Ganji.com, Energy Monster, Yuntion Semiconductor, Machenike, Yunsheng Intelligence, Anxin Network Shield, and BioMap.

BlueRun Ventures has been ranked first in Zero2IPO's "Top 30 Early-Stage Investment Institutions in China," first in ChinaVenture's "Top 30 Best Early-Stage Venture Capital Institutions in China," and among Preqin's Top 10 VC fund managers globally for consistent high-return performance.

The firm has also received consecutive annual recognition from Forbes China, 36Kr, Cyzone, Caixin Media, CBNweekly, Jiemian, and other media organizations as "China's Best Early-Stage Institution of the Year," "China's Top Venture Capital Firm," "Most Entrepreneur-Friendly Early-Stage Institution of the Year," and "Most Influential Early-Stage Institution of the Year."